Dr Thomas Newsom-Davis, Consultant Medical Oncologist

Dr Thomas Newsom-Davis

Consultant Medical Oncologist

Book online
|

Dr Thomas Newsom-Davis BSc MBBS FRCP PhD

Consultant Medical Oncologist

BSc MBBS FRCP PhD

Dr Thomas Newsom-Davis

Consultant Medical Oncologist BSc MBBS FRCP PhD

Book online
|
BSc MBBS FRCP PhD

Areas of expertise

  • Chemotherapy
  • Lung cancer
  • Mesothelioma
  • Thymus gland cancer
  • Primary lung tumours

Recommendations for Dr Newsom-Davis

These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.

Recommended by:

  • byDr Neal Navani, Consultant in Respiratory Medicine

    Dr Tom Newsom Davis is a key opinion leader in thoracic oncology, providing an excellent clinical service and latest clinical trials.

  • byDr Neal Navani, Consultant in Respiratory Medicine

    Dr Tom Newsom Davis is a key opinion leader in thoracic oncology, providing an excellent clinical service and latest clinical trials.

  • Address

    • LOC at Chelsea

      102 Sydney Street, Chelsea, London, SW3 6NJ

    • LOC - Leaders in Oncology Care

      95-97 Harley Street, London, W1G 6AF

    • Platinum Medical Centre

      15 - 17 Lodge Road, London, NW8 7JA

    • Sydney Street Outpatients and Diagnostics Centre

      102 Sydney Street, London, SW3 6NJ

    About Dr Thomas Newsom-Davis

    GMC number: 4529260

    Year qualified: 1998

    Place of primary qualification: University of London

    Areas of expertise

    • Lung Cancer
    • Mesothelioma
    • Acute Oncology
    • Other thoracic malignancies
    • Medical Oncology
    • Breast Cancers

    Professional memberships

    Royal College of Physicians
    General Medical Council

    Articles by Dr Thomas Newsom-Davis

    Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy

    Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy

    30-day mortality following initiation of immunotherapy for advanced stage lung cancer

    Emergency diagnosis of lung cancer: an international problem